HC Wainwright Analysts Reduce Earnings Estimates for Nkarta

Nkarta, Inc. (NASDAQ:NKTX) – Analysts at HC Wainwright reduced their Q3 2026 earnings estimates for Nkarta in a research note issued to investors on Tuesday, August 11th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.46) per share for the quarter, down from their previous estimate of ($0.41). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Nkarta’s current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Nkarta’s Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.26) EPS, FY2028 earnings at ($1.76) EPS, FY2029 earnings at ($1.53) EPS and FY2030 earnings at ($1.23) EPS.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.18).

A number of other equities research analysts have also weighed in on NKTX. TD Cowen began coverage on shares of Nkarta in a report on Tuesday, June 23rd. They set a “buy” rating on the stock. Evercore set a $9.00 price target on Nkarta in a research note on Monday, May 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Nkarta in a research note on Wednesday, June 24th. Wall Street Zen raised Nkarta from a “strong sell” rating to a “sell” rating in a report on Sunday, August 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Nkarta in a report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Nkarta currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.40.

Nkarta Stock Performance

Nkarta stock opened at $2.39 on Thursday. The stock has a 50-day moving average of $2.65 and a two-hundred day moving average of $2.58. Nkarta has a one year low of $1.70 and a one year high of $3.72. The stock has a market cap of $170.98 million, a PE ratio of -1.52 and a beta of 0.93.

Institutional Trading of Nkarta

Institutional investors have recently added to or reduced their stakes in the stock. Abel Hall LLC acquired a new stake in shares of Nkarta during the fourth quarter worth about $27,000. The Manufacturers Life Insurance Company purchased a new position in Nkarta in the first quarter valued at $30,000. Pallas Capital Advisors LLC purchased a new stake in Nkarta during the 2nd quarter worth about $31,000. Dynamic Technology Lab Private Ltd acquired a new position in Nkarta in the fourth quarter valued at approximately $37,000. Finally, Forefront Analytics LLC purchased a new stake in Nkarta in the second quarter valued at $82,000. Institutional investors and hedge funds own 80.54% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.